Yiman's practice focuses on cross-border M&A, private equity transactions, venture capital financings, public M&A, general corporate matters, and regulatory matters.

Before joining the Private Equity/M&A team, she spent several years advising multinational clients in the life sciences and technology sectors on complex internal investigations, white-collar matters, anti-corruption issues, and regulatory compliance.

Yiman is fluent in Mandarin, English, and Cantonese.

Representative Experience

• The Independent Directors Committee of Alibaba Group in the acquisition by Alibaba Group of a 33% stake of Ant Group, operator of China’s biggest online payment platform by market share.
• Happiness Capital as lead investor in connection with the US$3.3 million investment in Gozen Bioworks, a U.S. and Turkish based developer of the vegan and plastic-free "Lunaform" biomaterial, produced by microorganisms during a fermentation process.
• An international asset management firm as one of the major investors in connection with the Series B financing of a leading data center customization and operation service provider in China.
• A global education company in its approximately US$700 million sale of a majority stake to a leading Asian private equity fund. The education company has a UK nexus and operates across Southeast Asia.
• The News Lens Co., Ltd. (TNL) in a series of transactions consisting of (i) its merger with Japan-based Mediagene Inc. and (ii) its de-SPAC with Blue Ocean Acquisition Corporation and its $275 million listing on NASDAQ.
• Silver Crest Acquisition Corporation (NASDAQ: SLCR), a publicly traded special purpose acquisition company, in connection with its business combination with TH International Limited, a master franchisee and operator of Tim Hortons coffee shops in China.
• An Asia-based private equity firm in its proposed leveraged buyout of one of the world’s largest designers and manufacturers of intimate apparel.
• Ascendent Capital Partners on its disposal of Etern Group Ltd., which indirectly holds 98% of the equity interest in a general hospital in Suzhou, to Hygeia, a Hong Kong listed healthcare company, for a total consideration of RMB1,734,600,000 (approximately US$267 million).
• Ascendent Capital Partners in its HK $360 million investment in China Automation Group Limited (SEHK.0569), provider of safety and critical control systems for the petrochemical, oil and gas, and railway industries, by way of an exchangeable bond, loan of which was provided to Araco Investment Limited, a shareholder of China Automation Group Limited.